archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • P | National Centre for Pharmacoeconomics
    which an economic evaluation is conducted e g healthcare payer society individual Pharmacoeconomics Pharmacoeconomics is the scientific discipline that evaluates the clinical economic and humanistic aspects of pharmaceutical products to provide health care decision makers providers and patients with valuable information for optimal outcomes and the allocation of health care resources Pharmacoeconomics incorporates health economics clinical evaluations risk analysis technology assessment and health related quality of life epidemiology decision sciences and health services research Probabilistic sensitivity analysis PSA Type of sensitivity analysis in which probability distributions are specified for parameters e g outcomes costs utilities to capture the uncertainty around the true parameter value A Monte Carlo simulation is performed to generate a probability distribution of expected outcomes and costs Probability distribution Portrays the relative likelihood that a range of values is the true value of a treatment effect or other outcome or result This distribution may follow the form of a particular function e g a normal chi square binomial or Poisson distribution An estimate of the most likely true value of the treatment effect is the value at the highest point of the distribution The area under the curve between any two points along the range gives the

    Original URL path: http://www.ncpe.ie/category/glossary/p/ (2015-10-30)
    Open archived version from archive

  • Q | National Centre for Pharmacoeconomics
    Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Glossary Q In this Section About Us Current Staff News Glossary Contact Us Vacancies A B C D E H I M N O P Q R S T U V W Quality adjusted life year QALY A health outcome measure that adjusts years of life subsequent to an intervention by the

    Original URL path: http://www.ncpe.ie/category/glossary/q/ (2015-10-30)
    Open archived version from archive

  • R | National Centre for Pharmacoeconomics
    Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction GEJ adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy for whom treatment in combination with paclitaxel is not appropriate Rapid Review Commenced Completed Outcome 20 12

    Original URL path: http://www.ncpe.ie/category/glossary/r/ (2015-10-30)
    Open archived version from archive

  • S | National Centre for Pharmacoeconomics
    Wort Pacifa Pacifa is indicated for the short term treatment of mild depressive symptoms Rapid Review Commenced Completed Outcome 14 04 2015 29 05 2015 Full Pharmacoeconomic Evaluation Recommended Statistical significance A conclusion that an intervention has a true effect based upon observed differences in outcomes between the treatment and control groups that are sufficiently large so that these differences are unlikely to have occurred due to chance as determined

    Original URL path: http://www.ncpe.ie/category/glossary/s/ (2015-10-30)
    Open archived version from archive

  • T | National Centre for Pharmacoeconomics
    D E H I M N O P Q R S T U V W Insulin Degludec Tresiba Treatment of diabetes mellitus Rapid Review Commenced Completed Outcome 17 12 2012 04 01 2013 Full Pharmacoeconomic Assessment Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 04 11 2014 04 05 2015 Reimbursement Not Recommended at the submitted price Summary Technology In pharmacoeconomic evaluation technology is used to mean a drug or other treatment

    Original URL path: http://www.ncpe.ie/category/glossary/t-glossary/ (2015-10-30)
    Open archived version from archive

  • U | National Centre for Pharmacoeconomics
    Us Vacancies A B C D E H I M N O P Q R S T U V W Uncertainty a state in which the true value of a parameter or the structure of a process is unknown Utility A measure of preference for a specific health outcome obtained by methods that involve uncertainty e g standard gamble approach Utilities are usually expressed on a cardinal scale of zero

    Original URL path: http://www.ncpe.ie/category/glossary/u/ (2015-10-30)
    Open archived version from archive

  • V | National Centre for Pharmacoeconomics
    Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Glossary V In this Section About Us Current Staff News Glossary Contact Us Vacancies A B C D E H I M N O P Q R S T U V W Value of information VOI value of information techniques assess the expected costs of uncertainty surrounding a decision made on the basis of current information in order to

    Original URL path: http://www.ncpe.ie/category/glossary/v/ (2015-10-30)
    Open archived version from archive

  • W | National Centre for Pharmacoeconomics
    Utilisation Research Pharmacoeconomic Research ICORN Education Glossary W In this Section About Us Current Staff News Glossary Contact Us Vacancies A B C D E H I M N O P Q R S T U V W Willingness to pay WTP Evaluation method used to determine the maximum amount of money an individual is willing to pay for a particular outcome or benefit e g to receive a health

    Original URL path: http://www.ncpe.ie/category/glossary/w/ (2015-10-30)
    Open archived version from archive